Statistical issues in the evaluation of screening and early detection modalities

被引:7
作者
Etzioni, Ruth [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
关键词
prostate-specific antigen; mass screening; sensitivity; specificity; ROC curve; case-control study; verification bias;
D O I
10.1016/j.urolonc.2006.11.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thorough evaluation of a screening test requires conducting a series of studies to ascertain its ability to detect accurately disease, as well as its benefits and costs. In this article, I review the steps involved in evaluating a screening test, using the case of prostate-specific antigen (PSA) screening for prostate cancer as a case study. I discuss designs for quantifying the diagnostic properties of a screening test and compare several different studies that have produced quite different estimates of the diagnostic accuracy of PSA screening. I also review methods that may be used to combine other markers or tests with PSA to improve test accuracy. Determining the benefits of a screening test is complex, particularly when information from randomized trials is lacking. I review several observational studies of PSA benefit and discuss the use of computer models for inferring the impact of screening from trends in population mortality. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 32 条
[1]   ASSESSMENT OF DIAGNOSTIC-TESTS WHEN DISEASE VERIFICATION IS SUBJECT TO SELECTION BIAS [J].
BEGG, CB ;
GREENES, RA .
BIOMETRICS, 1983, 39 (01) :207-215
[2]   DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
BASLER, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08) :948-954
[3]   Semiparametric regression for the area under the receiver operating characteristic curve [J].
Dodd, LE ;
Pepe, MS .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2003, 98 (462) :409-417
[4]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[5]  
Etzioni R, 2004, CANCER EPIDEM BIOMAR, V13, P1640
[6]  
Etzioni R, 1998, AM J EPIDEMIOL, V148, P775
[7]   Combining biomarkers to detect disease with application to prostate cancer [J].
Etzioni, R ;
Kooperberg, C ;
Pepe, M ;
Smith, R ;
Gann, PH .
BIOSTATISTICS, 2003, 4 (04) :523-538
[8]   Cancer surveillance series: Interpreting trends in prostate cancer - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality [J].
Etzioni, R ;
Legler, JM ;
Feuer, EJ ;
Merrill, RM ;
Cronin, KA ;
Hankey, BF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1033-1039
[9]  
Etzioni R, 2002, J NATL CANCER I, V94, P981
[10]   Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates [J].
Feuer, EJ ;
Mariotto, A ;
Merrill, R .
CANCER, 2002, 95 (04) :870-880